336 related articles for article (PubMed ID: 24491302)
1. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.
Gambacorti Passerini C; Farina F; Stasia A; Redaelli S; Ceccon M; Mologni L; Messa C; Guerra L; Giudici G; Sala E; Mussolin L; Deeren D; King MH; Steurer M; Ordemann R; Cohen AM; Grube M; Bernard L; Chiriano G; Antolini L; Piazza R
J Natl Cancer Inst; 2014 Feb; 106(2):djt378. PubMed ID: 24491302
[TBL] [Abstract][Full Text] [Related]
2. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
Malik SM; Maher VE; Bijwaard KE; Becker RL; Zhang L; Tang SW; Song P; Liu Q; Marathe A; Gehrke B; Helms W; Hanner D; Justice R; Pazdur R
Clin Cancer Res; 2014 Apr; 20(8):2029-34. PubMed ID: 24573551
[TBL] [Abstract][Full Text] [Related]
3. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
4. Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.
Cui S; Zhao Y; Dong L; Gu A; Xiong L; Qian J; Zhang W; Niu Y; Pan F; Jiang L
Cancer Med; 2016 Jun; 5(6):1013-21. PubMed ID: 26880708
[TBL] [Abstract][Full Text] [Related]
5. EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer.
Wang Y; Zhang J; Gao G; Li X; Zhao C; He Y; Su C; Zhang S; Chen X; Zhang J; Li W; Li B; Zhao J; Hou L; Wu C; Ren S; Zhou C; Zhang J
J Thorac Oncol; 2015 Nov; 10(11):1546-52. PubMed ID: 26352533
[TBL] [Abstract][Full Text] [Related]
6. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of the anaplastic lymphoma kinase.
Mologni L
Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
Di Maio M; De Marinis F; Hirsch FR; Gridelli C
Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
10. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
11. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
[TBL] [Abstract][Full Text] [Related]
12. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
13. Experience in integrating ALK testing and crizotinib into the routine treatment of patients with non-small cell lung cancer.
Gautschi O; Schefer H; Riklin C; Strobel K; Diebold J
Onkologie; 2013; 36(6):342-7. PubMed ID: 23774148
[TBL] [Abstract][Full Text] [Related]
14. Crizotinib resistance in acute myeloid leukemia with inv(2)(p23q13)/RAN binding protein 2 (RANBP2) anaplastic lymphoma kinase (ALK) fusion and monosomy 7.
Takeoka K; Okumura A; Maesako Y; Akasaka T; Ohno H
Cancer Genet; 2015 Mar; 208(3):85-90. PubMed ID: 25766836
[TBL] [Abstract][Full Text] [Related]
15. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
Lee JA; Bubendorf L; Stahel R; Peters S
Expert Rev Anticancer Ther; 2013 May; 13(5):625-36. PubMed ID: 23617353
[TBL] [Abstract][Full Text] [Related]
16. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
17. Treatment of ALK-positive non-small cell lung cancer.
Bang YJ
Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
[TBL] [Abstract][Full Text] [Related]
18. Promising Effect of Crizotinib on Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer in an Elderly Patient with a Poor Performance Status: A Case Report and Literature Review.
Matsuo N; Sekine A; Kato T; Hosoda C; Ito H; Baba T; Umeda S; Iwasawa T; Okudela K; Ogura T
Intern Med; 2016; 55(5):507-9. PubMed ID: 26935372
[TBL] [Abstract][Full Text] [Related]
19. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.
Li T; LoRusso P; Maitland ML; Ou SH; Bahceci E; Ball HA; Park JW; Yuen G; Tolcher A
J Hematol Oncol; 2016 Mar; 9():23. PubMed ID: 26966027
[TBL] [Abstract][Full Text] [Related]
20. Crizotinib: an anaplastic lymphoma kinase inhibitor.
Gadgeel SM; Bepler G
Future Oncol; 2011 Aug; 7(8):947-53. PubMed ID: 21823889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
